Search
  • Within this site
AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

A Novel Nitric-Oxide Releasing Drug


Technology Benefits

Direct release of NO at physiological temperature and pH. More potent than equimolar amounts of nitroglycerin. Development of patient tolerance should not occur. No toxic by-products or concurrently released agents. Repeated administration regimens or development of time released formulations possible.


Detailed Technology Description

This hypertensive agent, nitrosyl-cobinamide, is a direct NO releasing agent that does not require biotransformation, thereby avoiding the concurrent release of toxic metabolites (superoxide ions, peroxynitrate, or cyanide ions). Cobinamide is a precursor of Vitamin B12 and appears to be metabolically neutral at the doses used for this indication. It has been tested in mammalian cells, Drosophila melanogaster and mice, where a rapid reduction of blood pressure was demonstrated.


Supplementary Information

Patent Number: US9093654B2
Application Number: US13022242A
Inventor: Che, Chi Ming | Xiang, Hai Feng
Priority Date: 9 Feb 2010
Priority Number: US9093654B2
Application Date: 7 Feb 2011
Publication Date: 28 Jul 2015
IPC Current: H01L005146 | B82Y001000 | H01L00310224 | H01L005100 | H01L005130 | H01L005142
US Class: 1001
Assignee Applicant: The University of Hong Kong
Title: Bis-(8-quinolinolato-N,O)platinum(II) based organic photovoltaic cell
Usefulness: Bis-(8-quinolinolato-N,O)platinum(II) based organic photovoltaic cell
Summary: The organic photovoltaic cell is useful to generate electricity.
Novelty: Organic photovoltaic cell, useful to generate electricity, comprises an organic photoactive layer comprising substituted bis-(8-quinolinolato-N,O)platinum(II) complexes


Industry

Functional Design


Sub Group

Mechanical Structure


Application No.

8222242


Others

State Of Development

Development for the use of this compound is at the prototype stage and efficacy in reducing blood pressure has been demonstrated. Ongoing pre-clinical studies continue, including pharmacokinetic and toxicology.


Additional Technologies by these Inventors


Tech ID/UC Case

19637/2007-196-0


Related Cases

2007-196-0


Country/Region

USA

For more information, please click Here
Business of IP Asia Forum
Desktop View